66th Annual Scientific Sessions of the American College of Cardiology 2017

Prof Kausik Ray: Analyses FOURIER, SPIRE-2 and ODYSSEY outcomes

SPIRE trials: Bococizumab was insufficiently humanized for long-term use

The development of bococizumab, the third of the PCSK9 monoclonal antibodies, was discontinued by Pfizer in early November (1). Insights from a late breaker trial presentation provide some answers why this might be the case. SPIRE programme: lipid lowering trials The SPIRE program included 6…

SPIRE-2: Cardiovascular benefit in very high risk patients

Evidence from the two cardiovascular outcomes studies with bococizumab, notably SPIRE-2, added to the buzz around FOURIER. According to PCSK9 Forum Editor Professor Philip Barter (University of New South Wales, Sydney, Australia): ‘Despite follow-up being short due to termination of the development of bococizumab, SPIRE-2…

A landmark day for PCSK9 inhibition

What a landmark day for lipid lowering. All eyes were focused on FOURIER at the first of the late-breaking clinical trial sessions at ACC.2017. And the results didn’t disappoint. In patients with stable cardiovascular disease on maximally tolerated statin therapy, evolocumab treatment lowered LDL cholesterol…

Prof Henry Ginsberg: Data needed on the diabetes subgroup in FOURIER

Prof Raul Santos: SPIRE trials with bococizumab

The data from the SPIRE programme, especially SPIRE-1 and SPIRE-2 the cardiovascular outcomes studies was also illuminating. PCSK9 Forum Editor Professor Raul Santos, one of the authors, gives his view.

Prof Philip Barter: How do we translate the FOURIER data to clinical practice?

Prof John Chapman: FOURIER – Why was there no significant effect on CV mortality?

Prof John Chapman: FOURIER endpoint data

PCSK9 Forum Editor Professor Philip Barter discusses FOURIER

Take home message on FOURIER

FOURIER: a landmark trial

Treatment with evolocumab on top of maximally tolerated statin led to significant reduction in the risk of major cardiovascular events, the primary study endpoint, by 15% (p<0.001), as well as a 20% reduction in the risk of the secondary ‘hard outcomes’ endpoint, a composite of…

PCSK9 Forum Editor Professor Henry Ginsberg discusses FOURIER